Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rhu-pGSN in severe COVID-19 pneumonia
NCT04358406Phase 2Completed
- Sponsor
- BioAegis Therapeutics
- Start
- Jul 2020
- Primary completion
- May 2021
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 2
01
Overview
A Phase 2 trial of Recombinant human plasma gelsolin in COVID-19 pneumonia, sponsored by BioAegis Therapeutics. Started Jul 2020; status: completed.
02
Drugs
Recombinant human plasma gelsolin
03
Conditions
COVID-19 pneumonia
Beyond the preview
Go deeper on NCT04358406.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04358406.